Liquidia Corporation LQDA Yutrepia — Program Expenses

Similar metrics at other companies

PRAXRelutrigine — Program-specific expenses

$12.85M+139%

GILDYeztugo — Total revenues

$166M—

VTRSYupelri ® — Net Sales

$62.5M+7.2%

ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$14.34M+9.7%

NUVLZidesamtinib — Direct Expenses Related To Program

$12.31M-20.8%

RPRXPhase 2b, TEV-408 — Research and development funding expense

$14.3M—

Questions, answered.

What is Liquidia Corporation's yutrepia — program expenses?

Liquidia Corporation (LQDA) reported yutrepia — program expenses of $15.89M in Q1 2026.

How has Liquidia Corporation's yutrepia — program expenses changed year-over-year?

Liquidia Corporation's yutrepia — program expenses increased by 62.8% year-over-year, from $9.76M to $15.89M.

What is the long-term trend for Liquidia Corporation's yutrepia — program expenses?

Over 2 years (2023 to 2025), Liquidia Corporation's yutrepia — program expenses has grown at a 53.6% compound annual growth rate (CAGR), from $23.49M to $55.44M.

What does yutrepia — program expenses mean?

This metric represents the direct research, development, and commercialization costs specifically allocated to the Yutrepia product line. It captures the investment intensity required to advance the product through clinical trials, regulatory approval, and market launch phases. Monitoring this helps investors assess the capital commitment dedicated to the company's primary therapeutic asset.